Virios Therapeutics (NASDAQ:VIRI) Coverage Initiated by Analysts at Maxim Group

Maxim Group started coverage on shares of Virios Therapeutics (NASDAQ:VIRI) in a research report report published on Thursday morning, Benzinga reports. The firm issued a buy rating and a $1.00 target price on the stock.

Virios Therapeutics Trading Up 4.4 %

Shares of VIRI stock opened at $0.26 on Thursday. The firm’s 50 day moving average is $0.33 and its 200 day moving average is $0.44. The stock has a market capitalization of $5.01 million, a P/E ratio of -0.96 and a beta of 1.62. Virios Therapeutics has a 12 month low of $0.16 and a 12 month high of $2.42.

Virios Therapeutics (NASDAQ:VIRI) last posted its earnings results on Thursday, May 9th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.01. On average, equities analysts predict that Virios Therapeutics will post -0.27 EPS for the current year.

About Virios Therapeutics

Virios Therapeutics, Inc, a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.